KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Depreciation and Depletion: 2020-2025

Historic Depreciation and Depletion for AbCellera Biologics (ABCL) over the last 6 years, with Sep 2025 value amounting to $4.3 million.

  • AbCellera Biologics' Depreciation and Depletion rose 13.16% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year increase of 7.06%. This contributed to the annual value of $12.5 million for FY2024, which is 2.05% down from last year.
  • Latest data reveals that AbCellera Biologics reported Depreciation and Depletion of $4.3 million as of Q3 2025, which was down 4.44% from $4.5 million recorded in Q2 2025.
  • AbCellera Biologics' 5-year Depreciation and Depletion high stood at $4.5 million for Q2 2025, and its period low was $840,000 during Q1 2021.
  • Over the past 3 years, AbCellera Biologics' median Depreciation and Depletion value was $3.4 million (recorded in 2024), while the average stood at $3.5 million.
  • In the last 5 years, AbCellera Biologics' Depreciation and Depletion surged by 113.97% in 2022 and then crashed by 46.15% in 2024.
  • AbCellera Biologics' Depreciation and Depletion (Quarterly) stood at $1.3 million in 2021, then spiked by 113.97% to $2.8 million in 2022, then skyrocketed by 39.89% to $3.9 million in 2023, then plummeted by 46.15% to $2.1 million in 2024, then climbed by 13.16% to $4.3 million in 2025.
  • Its last three reported values are $4.3 million in Q3 2025, $4.5 million for Q2 2025, and $4.4 million during Q1 2025.